![[feed]](/style/images/feed-icon-14x14.png){kind=icon}
Tools
Tools
Preview |
PDF (Original Article)
- Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
751kB |
![[thumbnail of Supporting Information]](https://edoc.mdc-berlin.de/style/images/fileicons/other.png) |
Other (Supporting Information)
640kB |
| Item Type: | Article |
|---|---|
| Title: | Rapid proteomic analysis for solid tumors reveals LSD1 as a drug target in an end-stage cancer patient |
| Creators Name: | Doll, S., Kriegmair, M.C., Santos, A., Wierer, M., Coscia, F., Neil, H.M., Porubsky, S., Geyer, P.E., Mund, A., Nuhn, P. and Mann, M. |
| Abstract: | Recent advances in mass spectrometry (MS)-based technologies are now set to transform translational cancer proteomics from an idea to a practice. Here, we present a robust proteomic workflow for the analysis of clinically relevant human cancer tissues that allows quantitation of thousands of tumor proteins in several hours of measuring time and a total turnaround of a few days. We applied it to a chemorefractory metastatic case of the extremely rare urachal carcinoma. Quantitative comparison of lung metastases and surrounding tissue revealed several significantly upregulated proteins, among them lysine-specific histone demethylase 1 (LSD1/KDM1A). LSD1 is an epigenetic regulator and the target of active development efforts in oncology. Thus, clinical cancer proteomics can rapidly and efficiently identify actionable therapeutic options. While currently described for a single case study, we envision that it can be applied broadly to other patients in a similar condition. |
| Keywords: | Case Study, Clinical Proteomics, Epigenetics, Mass Spectrometry, Urachal Carcinoma |
| Source: | Molecular Oncology |
| ISSN: | 1574-7891 |
| Publisher: | Wiley |
| Volume: | 12 |
| Number: | 8 |
| Page Range: | 1296-1307 |
| Date: | August 2018 |
| Official Publication: | https://doi.org/10.1002/1878-0261.12326 |
| PubMed: | View item in PubMed |
Repository Staff Only: item control page
